OKYO vs STRO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
STRO Captures Institutional Edge (3โ1 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Sutro Biopharma, Inc. (STRO) driven by superior Valuation, Momentum & Technical, Options & Structure while OKYO counters with relative strength in Growth & Margin. Fundamentally, OKYO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus STRO at 10.0x Forward P/E and -254.7% operating margin (-6.1% YoY). In options structure, OKYO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against STRO sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | OKYO | STRO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $62.7M | $144.8M | Larger Scale | STRO |
| Trailing P/E Ratio Valuation | N/M | 10.0x | Lower Multiple | STRO |
| Forward P/E Ratio Valuation | N/M | 10.0x | Lower Multiple | STRO |
| Revenue Growth (YoY) Growth | +0.0% | -6.1% | Higher Growth | OKYO |
| Operating Margin (TTM) Profitability | 0.0% | -254.7% | Higher Margin | OKYO |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -263.8% | -1810.0% | Higher ROE | OKYO |
| 52-Week Range Position Momentum | 3% ($1โ$3) | 18% ($1โ$44) | Stronger Trend | STRO |
| Beta / 30D Volatility Risk Regime | 1.00ฮฒ ยท 76% Vol | 1.46ฮฒ ยท 76% Vol | Lower Realized Risk | Tie |
| Unified Institutional Score Composite Signal | 42.8 / 100 (HOLD) | 44.1 / 100 (HOLD) | Higher Composite | STRO |